Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CALML3 | P27482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5670931 | 0.94 | MAOA (0.88) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL5656741 | 0.93 | MAOA (0.87) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL4020689 | 0.92 | MAOA (0.85) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL5655236 | 0.92 | MAOA (0.85) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL5656832 | 0.92 | MAOA (0.84) | MAOACYP3A4CYP2D6KCNH2CALML3 | |
| SCHEMBL5655303 | 0.91 | MAOA (0.83) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL5656865 | 0.91 | MAOA (0.83) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL5656637 | 0.90 | MAOA (0.85) | MAOACYP3A4CYP2D6KCNH2CALML3 | |
| SCHEMBL5656310 | 0.90 | MAOA (1.00) | MAOACYP3A4CYP2D6KCNH2CALML3 | |
| SCHEMBL5655261 | 0.90 | MAOA (0.82) | MAOACYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199143-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-7199143-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-20050182112-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | disclosed |
| EP-1480975-A2 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072576-A2 | OXAZOLIDINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182112-A1 | Chemical compounds | CYP8B1, H1-0, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAOA 470/4885CYP3A4 31/4885CYP2D6 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.